rofecoxib

出典: meddic

ロフェコキシブ

WordNet   license wordnet

「a Cox-2 inhibitor (trade name Vioxx) that relieves pain and inflammation without harming the digestive tract; voluntarily withdrawn from the market in 2004」
Vioxx

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/12/25 01:50:35」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.
  • Moore A, Makinson G, Li C.AbstractABSTRACT: INTRODUCTION: While the safety of celecoxib has been investigated, there are limited data available on complications affecting the entire (upper and lower) gastrointestinal (GI) tract, with no patient-level pooled analyses of upper and lower GI outcomes available. We therefore evaluated the upper and lower GI safety of celecoxib using patient-level data from randomized controlled trials (RCTs).
  • Arthritis research & therapy.Arthritis Res Ther.2013 Jan 8;15(1):R6. [Epub ahead of print]
  • ABSTRACT: INTRODUCTION: While the safety of celecoxib has been investigated, there are limited data available on complications affecting the entire (upper and lower) gastrointestinal (GI) tract, with no patient-level pooled analyses of upper and lower GI outcomes available. We therefore evaluated th
  • PMID 23298471
  • Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy.
  • Castellsague J, Pisa F, Rosolen V, Drigo D, Riera-Guardia N, Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S.SourceRTI Health Solutions, Barcelona, Spain.
  • Pharmacoepidemiology and drug safety.Pharmacoepidemiol Drug Saf.2012 Dec 11. doi: 10.1002/pds.3385. [Epub ahead of print]
  • PURPOSE: Information on the risk of upper gastrointestinal complications (UGIC) in users of nimesulide, the most used nonsteroidal anti-inflammatory drug (NSAID) in Italy, is scarce. In the context of the European regulatory review on nimesulide, we estimated and compared the risk associated with ni
  • PMID 23229866

和文文献

  • Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats
  • MIYAJIMA Atsushi,OKAMOTO Masahiro,MUTO Takafumi,HIROTA Takashi
  • Journal of toxicological sciences 38(5), 719-729, 2013-10-01
  • NAID 10031191731
  • Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats
  • Miyajima Atsushi,Okamoto Masahiro,Muto Takafumi [他]
  • The Journal of toxicological sciences : an official journal of the Japanese Society of Toxicology 38(5), 719-729, 2013-10
  • NAID 40019828991
  • Disruption of elastic lamellae in aorta and dysfunction of vaso-regulation by rofecoxib in rats
  • , , ,
  • The Journal of Toxicological Sciences 38(5), 719-729, 2013
  • … We assessed the effects of rofecoxib on cross-linkage formation in elastin and vaso-regulatory function in rats. … After administration of rofecoxib at a dose of 10 mg/kg for 7 weeks to young rats and for 7 and 10 weeks to adult rats, thoracic aortas were isolated. … However, the content of cross-linkages in elastin, i.e. desmosine and isodesmosine, which give elasticity to the aortic wall, was not significantly different between the rofecoxib treated and control groups. …
  • NAID 130004903977

関連リンク

Rofecoxib gained widespread acceptance among physicians treating patients with arthritis and other conditions ... On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元ロフェコキシブ

ロフェコキシブ」

  [★]

rofecoxib
Vioxx
非ステロイド性抗炎症薬





★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡